Affinage

DEPDC1

DEP domain-containing protein 1A · UniProt Q5TB30

Length
811 aa
Mass
93.0 kDa
Annotated
2026-06-09
41 papers in source corpus 27 papers cited in narrative 27 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

DEPDC1 is a cell-cycle-regulated nuclear and centrosomal protein whose expression peaks in mitosis and is required for proper mitotic progression and bipolar spindle organization (PMID:17452976, PMID:25902835, PMID:28602627). Its isoform a localizes to the centrosome in metaphase in a manner dependent on phosphorylation at Ser110, with non-phosphorylatable mutants failing to rescue the centrosome disruption caused by DEPDC1 depletion, while isoform b localizes to the mitotic cell cortex; both isoforms are degraded upon mitotic exit (PMID:28602627). Loss of DEPDC1 produces mitotic arrest, multipolar spindles, and multinucleated cells (PMID:25902835, PMID:28969015). Beyond mitosis, DEPDC1 acts as a nuclear transcriptional co-regulator: it binds the zinc-finger repressor ZNF224 to suppress transcription of A20 (TNFAIP3), thereby de-repressing NF-κB signaling, and disrupting this complex with a competing peptide reactivates A20 and triggers apoptosis (PMID:20587513). DEPDC1 engages the transcription factors E2F1, to drive the G1-S transition (PMID:28634077), and FOXM1, promoting its nuclear translocation in a positive feedback loop that reinforces FOXM1 transcriptional activity (PMID:39004911, PMID:36072787). In response to anti-tubulin drugs, DEPDC1 promotes JNK-dependent phosphorylation and degradation of the anti-apoptotic factor MCL1, a function conserved with its C. elegans ortholog LET-99 acting upstream of G-protein/JNK signaling (PMID:25064737). Across diverse tumor types DEPDC1 functions upstream of oncogenic pathways including Wnt/β-catenin (PMID:34268303, PMID:35795985), RAS-ERK with associated autophagy and glycolysis control (PMID:33021072, PMID:39016842), and PI3K/AKT/mTOR (PMID:37955537, PMID:40600015), collectively promoting proliferation, invasion, angiogenesis, and chemoresistance. DEPDC1 levels are tightly controlled post-transcriptionally by multiple microRNAs and RNA-binding factors (PMID:30419349, PMID:34741030, PMID:38960258).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2007 Medium

    Established DEPDC1 as a nuclear protein required for cancer cell growth, defining it as a candidate proliferation driver.

    Evidence Immunocytochemistry and siRNA knockdown growth assay in bladder cancer cells

    PMID:17452976

    Open questions at the time
    • No molecular mechanism for the growth requirement
    • Localization shown only in one cancer type
  2. 2010 High

    Identified the first molecular mechanism: DEPDC1 binds ZNF224 to repress A20 and sustain NF-κB signaling, with peptide disruption inducing apoptosis.

    Evidence Reciprocal Co-IP, colocalization, cell-permeable competing peptide, in vitro and in vivo apoptosis assays

    PMID:20587513

    Open questions at the time
    • DNA-binding contribution of ZNF224 vs DEPDC1 not separated
    • Direct A20 promoter occupancy by the complex not shown
  3. 2014 High

    Placed DEPDC1 in a conserved JNK signaling axis controlling MCL1 turnover and anti-tubulin drug-induced apoptosis, using an ortholog to anchor pathway order.

    Evidence C. elegans RNAi screen, genetic epistasis with GPA-11/JNK-1, mammalian knockdown and MCL1 phosphorylation/degradation westerns

    PMID:25064737

    Open questions at the time
    • Direct biochemical link between DEPDC1 and JNK activation not defined
    • Whether DEPDC1 acts via a GTPase-regulatory function unknown
  4. 2015 Medium

    Demonstrated DEPDC1 expression peaks in mitosis and is required for mitotic progression, connecting the proliferation phenotype to spindle integrity.

    Evidence Cell synchronization, immunofluorescence, siRNA with mitotic phenotype and CCNB1/CCNB2/A20 expression analysis

    PMID:25902835

    Open questions at the time
    • Mechanism linking DEPDC1 to spindle bipolarity not resolved
    • Causal order between A20 upregulation and arrest unclear
  5. 2017 High

    Resolved isoform-specific localization and showed Ser110 phosphorylation is necessary for centrosomal targeting and centrosome integrity, providing the first structural-functional handle.

    Evidence Mass spectrometry phosphosite mapping, site-directed mutagenesis, siRNA rescue, immunofluorescence

    PMID:28602627

    Open questions at the time
    • Kinase responsible for Ser110 phosphorylation unknown
    • Centrosomal binding partners not identified
  6. 2017 Medium

    Expanded DEPDC1's transcriptional reach by showing it potentiates E2F1 activity to drive G1-S transition and confirming NF-κB axis upstream control across additional tumor types.

    Evidence Co-IP, flow cytometry cell cycle analysis, gain/loss-of-function with xenografts (E2F1); siRNA with pathway gene expression and invasion assays (NF-κB)

    PMID:28634077 PMID:28969015

    Open questions at the time
    • Direct vs indirect effect on E2F1 target promoters not dissected
    • Whether E2F1 and NF-κB effects share a common mechanism unclear
  7. 2019 Medium

    Extended DEPDC1 oncogenic output to chemokine (CCL20/CCR6) and JNK-mediated chemoresistance programs in hepatocellular carcinoma.

    Evidence siRNA/overexpression, microarray, epistatic rescue, JNK inhibitor SP600125, tube formation and viability assays, xenografts

    PMID:31189746 PMID:31322256

    Open questions at the time
    • Direct molecular targets of DEPDC1 within these pathways not defined
    • Connection to mitotic/centrosomal function unexplored
  8. 2021 Medium

    Defined upstream regulators (ALPK2, Linc-ROR/HNRNPK) and a Wnt/β-catenin output, framing DEPDC1 as both a regulated node and a driver of EMT-associated invasion.

    Evidence Co-IP (ALPK2), RNA pull-down/RIP and mRNA stability assays (Linc-ROR/HNRNPK), overexpression with Wnt/β-catenin and EMT markers, metastasis models

    PMID:34210956 PMID:34268303 PMID:34741030

    Open questions at the time
    • Whether ALPK2 phosphorylates DEPDC1 not tested
    • Direct molecular link from DEPDC1 to Wnt pathway components missing
  9. 2022 Medium

    Mapped multilayered transcriptional and epigenetic control of DEPDC1 (FOXO3a repression, SIRT1/miR-20b-3p axis) and consolidated FOXM1 as a physical partner promoting Wnt signaling.

    Evidence ChIP, dual-luciferase reporter, Co-IP and immunofluorescence, drug-resistance and functional assays

    PMID:35795985 PMID:36072787 PMID:36200529

    Open questions at the time
    • Stoichiometry and structural basis of DEPDC1-FOXM1 interaction unknown
    • Integration of competing regulators in a single cell context not shown
  10. 2023 Medium

    Identified kinesin partners (KIF4A) and Hippo, PI3K/AKT/mTOR, and glycolytic outputs, linking DEPDC1 to cytoskeletal motors and metabolic reprogramming.

    Evidence Co-IP, KIF4A/S100A16 rescue epistasis, western blots for Hippo and PI3K/Akt/mTOR proteins, glycolysis and angiogenesis assays

    PMID:36768316 PMID:36849972 PMID:37955537

    Open questions at the time
    • Whether kinesin binding relates to mitotic spindle function untested
    • Causal hierarchy among the multiple downstream pathways unresolved
  11. 2024 High

    Established a FOXM1-DEPDC1 positive feedback loop and additional RAS-ERK (via TTK), AKT/mTOR/HIF1α, and TGF-β mechanisms underlying tumorigenesis and TKI resistance.

    Evidence ChIP, Co-IP, nuclear fractionation, luciferase, multi-omics, drug-resistance assays and in vivo models

    PMID:38960258 PMID:39004911 PMID:39016842 PMID:39068164

    Open questions at the time
    • How a single protein coordinates so many distinct pathways mechanistically unclear
    • Whether these reflect direct biochemical activities or indirect transcriptional effects undefined
  12. 2025 Medium

    Defined translational and motor-protein control of DEPDC1 (METTL5/m6A 18S rRNA, KIF20A), reinforcing post-transcriptional regulation and PI3K/AKT/mTOR coupling.

    Evidence Overexpression/knockdown with DEPDC1 protein westerns, Co-IP, pathway analysis, in vivo tumor models

    PMID:40018408 PMID:40600015

    Open questions at the time
    • Specificity of METTL5 effect on DEPDC1 versus global translation not isolated
    • KIF20A-DEPDC1 functional relationship to spindle biology untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • The core biochemical activity of DEPDC1 — whether it acts enzymatically, as a scaffold, or as a GTPase regulator via its DEP domain — remains undefined, leaving open how a mitotic centrosomal protein controls such diverse cytoplasmic and transcriptional pathways.
  • No structural model or domain-function map
  • No reconstituted biochemical activity
  • Mechanism unifying mitotic, transcriptional, and signaling roles unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 3 GO:0098772 molecular function regulator activity 2
Localization
GO:0005634 nucleus 2 GO:0005856 cytoskeleton 2 GO:0005815 microtubule organizing center 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1640170 Cell Cycle 3 R-HSA-1643685 Disease 3
Partners
ALPK2E2F1FOXM1KIF20AKIF4AS100A16TTKZNF224

Evidence

Reading pass · 27 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2007 DEPDC1 protein localizes to the nucleus of bladder cancer cells, as detected by immunocytochemical staining, and siRNA-mediated knockdown of DEPDC1 significantly inhibits growth of bladder cancer cells. Immunocytochemical staining, siRNA knockdown with cell growth assay Oncogene Medium 17452976
2010 DEPDC1 physically interacts with the zinc finger transcriptional repressor ZNF224 and colocalizes with it in the nucleus; this interaction suppresses transcription of A20 (TNFAIP3), an inhibitor of NF-κB signaling, and disrupting the DEPDC1-ZNF224 complex with a cell-permeable peptide triggers A20 transcriptional activation and apoptosis in bladder cancer cells. Co-immunoprecipitation, immunocytochemistry, cell-permeable peptide competition, in vitro and in vivo apoptosis assays Cancer research High 20587513
2014 In C. elegans, the DEPDC1 ortholog LET-99 acts upstream of the heterotrimeric G-protein alpha subunit GPA-11 to control activation of the stress kinase JNK-1 in response to microtubule-targeting drugs (vincristine); human DEPDC1 similarly promotes JNK-dependent phosphorylation and degradation of the anti-apoptotic BCL-2 family member MCL1, mediating anti-tubulin drug-induced apoptosis. RNAi-based screen in C. elegans, genetic epistasis, mammalian cell knockdown, western blot for MCL1 phosphorylation/degradation, JNK inhibitor experiments Nature cell biology High 25064737
2015 DEPDC1 expression peaks during mitosis in synchronized cells; siRNA-mediated knockdown causes mitotic arrest, multipolar spindle structures, and abnormal multinucleated cells, accompanied by upregulation of A20 and cell cycle genes CCNB1 and CCNB2, establishing a direct role for DEPDC1 in proper mitotic progression. Cell synchronization, immunofluorescence, siRNA knockdown with mitotic phenotype analysis, gene expression analysis BMB reports Medium 25902835
2017 DEPDC1 isoform a (DEPDC1a) localizes to the centrosome in metaphase and is required for centrosome integrity and bipolar spindle organization; phosphorylation of DEPDC1 at Ser110 (identified by mass spectrometry) is essential for its centrosomal localization, and non-phosphorylatable Ser110 mutants fail to rescue centrosome disruption caused by DEPDC1 depletion. DEPDC1 isoform b localizes to the cell cortex during mitosis. Both isoforms are upregulated in mitosis and degraded upon mitotic exit. Mass spectrometry, immunofluorescence, site-directed mutagenesis, siRNA rescue experiments, subcellular fractionation/localization Experimental cell research High 28602627
2017 DEPDC1 interacts with the transcription factor E2F1, increasing its transcriptional activity, thereby activating E2F signaling and promoting G1-S phase cell cycle transition in prostate cancer cells. Co-immunoprecipitation, cell cycle analysis (flow cytometry), overexpression and knockdown with proliferation assays, in vivo xenograft Biochemical and biophysical research communications Medium 28634077
2017 DEPDC1 depletion in nasopharyngeal carcinoma cells causes mitotic arrest with multipolar spindles and multiple nuclei, upregulates A20, and downregulates NF-κB downstream targets (c-Myc, BCL2, CCND1, CCNB1, CCNB2) as well as metastasis-associated genes (MMP2, MMP9, ICAM1, vimentin, Twist1), placing DEPDC1 upstream of NF-κB pathway regulation and cell motility. siRNA knockdown, immunofluorescence, gene expression analysis, migration/invasion assays, in vivo xenograft Oncotarget Medium 28969015
2018 miR-26b directly represses DEPDC1 expression, and DEPDC1 promotes cell proliferation and tumor growth in triple-negative breast cancer by increasing expression of the transcription factor FOXM1. miRNA overexpression/inhibition, DEPDC1 knockdown/overexpression, luciferase reporter assay (implied by direct repression), colony formation and tumor growth assays, western blot for FOXM1 Cancer letters Medium 30419349
2019 DEPDC1 knockdown in hepatocellular carcinoma cells significantly reduces expression of CCL20 and CCR6, and DEPDC1 drives HCC proliferation, invasion, and angiogenesis via the CCL20/CCR6 signaling pathway; CCL20 or CCR6 knockdown reverses the pro-angiogenic effects of DEPDC1 overexpression. siRNA knockdown, DNA microarray, qRT-PCR, western blot, invasion assay, tube formation assay, in vivo xenograft Oncology reports Medium 31322256
2019 DEPDC1 promotes HCC cell viability and resistance to chemotherapy (oxaliplatin) through the JNK signaling pathway, as demonstrated by reversal of DEPDC1 pro-survival effects with the JNK-specific inhibitor SP600125. siRNA knockdown, overexpression, JNK inhibitor (SP600125) treatment, CCK-8 viability assay, flow cytometry, in vivo xenograft Bioscience reports Medium 31189746
2020 DEPDC1 upregulates RAS expression and consequently enhances ERK1/2 activity in lung adenocarcinoma cells, through which DEPDC1 inhibits autophagy; knockdown of DEPDC1 impairs proliferation, migration, and invasion. siRNA knockdown, overexpression, western blot for RAS and phospho-ERK1/2, autophagy markers, cell functional assays Journal of cellular and molecular medicine Medium 33021072
2020 NNK (tobacco carcinogen) stimulates DEPDC1 expression by promoting DNMT1-mediated methylation of the DEPDC1 gene body in OSCC cells; upregulated DEPDC1 in turn promotes OSCC cell proliferation by inhibiting CYP27B1 expression. In vitro NNK treatment, DNMT1 overexpression, DEPDC1 knockdown/overexpression, CYP27B1 expression analysis, in vivo tumor growth assay American journal of cancer research Medium 32642287
2021 ALPK2 directly interacts with DEPDC1A in bladder cancer cells, and DEPDC1A functions as a downstream effector of ALPK2; overexpression of DEPDC1A rescues the inhibitory effects of ALPK2 knockdown on bladder cancer cell proliferation, apoptosis, and migration. Co-immunoprecipitation (direct interaction), siRNA knockdown, overexpression rescue, in vitro and in vivo functional assays Cell death & disease Medium 34210956
2021 Linc-ROR acts as competing endogenous RNA to stabilize DEPDC1 mRNA and also regulates DEPDC1 mRNA stability by binding the RNA-binding protein HNRNPK, thereby promoting HCC progression and angiogenesis. lncRNA knockdown/overexpression, RNA pull-down/RIP for HNRNPK interaction, mRNA stability assay, functional assays Cell death & disease Medium 34741030
2021 DEPDC1 promotes HCC migration and invasion via activation of Wnt/β-catenin signaling and epithelial-mesenchymal transition, as demonstrated by downregulation of Wnt1 and β-catenin upon DEPDC1 reduction. Lentiviral DEPDC1 overexpression, in vitro migration/invasion assays, western blot for Wnt/β-catenin and EMT markers, in vivo bioluminescence metastasis model Frontiers in cell and developmental biology Medium 34268303
2022 SIRT1 binds to the promoter of miR-20b-3p to repress its expression, thereby de-repressing DEPDC1 (a direct target of miR-20b-3p), and this SIRT1/miR-20b-3p/DEPDC1 axis mediates oxaliplatin resistance in colorectal cancer. ChIP (SIRT1 promoter binding), luciferase reporter assay (miR-20b-3p/DEPDC1 targeting), siRNA knockdown, drug resistance assays Cell biology international Medium 36200529
2022 FOXO3a binds to the DEPDC1 promoter and represses its transcription; DEPDC1 in turn promotes nephroblastoma cell proliferation, invasion, and migration via activation of Wnt/β-catenin signaling (increasing phospho-GSK-3β, Wnt3a, and β-catenin); DEPDC1 overexpression reverses the inhibitory effects of FOXO3a overexpression. Co-immunoprecipitation, dual-luciferase reporter assay, siRNA/overexpression, western blot for Wnt/β-catenin pathway proteins, functional cellular assays Molecular medicine reports Medium 35795985
2022 DEPDC1 interacts with FOXM1 (confirmed by Co-IP and immunofluorescence in OSCC cells) and facilitates Wnt/β-catenin signal transduction and nuclear β-catenin accumulation, thereby promoting OSCC pathogenesis. Co-immunoprecipitation, immunofluorescence, overexpression/knockdown, western blot for β-catenin, in vivo tumor model Frontiers in oncology Medium 36072787
2023 DEPDC1 physically interacts with KIF4A (confirmed by Co-IP in osteosarcoma cells), and KIF4A overexpression partially reverses the effects of DEPDC1 knockdown on cell viability, proliferation, invasion, migration, and angiogenesis; DEPDC1 knockdown activates the Hippo pathway (increasing p-LATS1 and p-YAP), which is reversed by KIF4A upregulation. Co-immunoprecipitation, siRNA knockdown, overexpression, CCK-8, EdU staining, Transwell, wound healing, tube formation assay, western blot for Hippo pathway proteins Journal of orthopaedic surgery and research Medium 36849972
2023 DEPDC1 promotes aerobic glycolysis, migration, and invasion in oral squamous cell carcinoma via the WNT/β-catenin pathway. siRNA knockdown, overexpression, functional migration/invasion assays, glycolysis assays, western blot for WNT/β-catenin pathway markers International journal of molecular sciences Medium 36768316
2023 S100A16 directly binds DEPDC1 (confirmed by Co-IP), and DEPDC1 overexpression partially reverses the inhibitory effects of S100A16 knockdown on nephroblastoma cell proliferation, invasion, migration, and angiogenesis, acting through activation of the PI3K/Akt/mTOR pathway. Co-immunoprecipitation, siRNA knockdown, overexpression rescue, western blot for PI3K/Akt/mTOR proteins, functional cellular assays Polish journal of pathology Medium 37955537
2024 FOXM1 binds to the DEPDC1 promoter and transcriptionally induces DEPDC1 expression; in turn, DEPDC1 physically interacts with FOXM1, promotes its nuclear translocation, and reinforces its transcriptional activity, constituting a positive feedback loop that drives hepatocarcinogenesis. Chromatin immunoprecipitation (ChIP) for FOXM1 promoter binding, Co-immunoprecipitation for DEPDC1-FOXM1 interaction, nuclear fractionation, luciferase reporter assay, knockdown rescue experiments, in vivo HCC model Cancer science High 39004911
2024 DEPDC1 knockdown reverses tyrosine kinase inhibitor (TKI) resistance in renal cell carcinoma cell lines; bulk RNA-seq and non-targeted metabolomics combined with protein-level analysis indicate that DEPDC1 regulates glycolysis via the AKT/mTOR/HIF1α pathway. scRNA-seq, siRNA knockdown, RNA-seq, non-targeted metabolomics, western blot for AKT/mTOR/HIF1α pathway proteins, drug resistance assays Cell death & disease Medium 39068164
2024 DEPDC1 upregulates RAS expression through TTK (phosphotyrosine-picked threonine tyrosine kinase), enhancing ERK activity, and thereby regulates glycolysis and autophagy in osteosarcoma cells; DEPDC1-TTK interaction is predicted by STRING and confirmed by co-immunoprecipitation. Co-immunoprecipitation, siRNA knockdown, western blot for RAS/ERK, glycolysis assays (ECAR, glucose uptake, lactate), autophagy markers Anti-cancer drugs Medium 39016842
2024 miR-130b-3p directly binds to the 3'UTR of DEPDC1 mRNA to suppress its expression; DEPDC1 levels affect NSCLC cell proliferation, migration, and apoptosis via TGF-β signaling pathway. Dual-luciferase reporter assay (3'UTR binding), miRNA overexpression/inhibition, DEPDC1 knockdown/overexpression, western blot for TGF-β pathway markers, functional assays International journal of biological macromolecules Medium 38960258
2025 The m6A methyltransferase METTL5 promotes DEPDC1 translation via m6A modification of 18S rRNA; METTL5 overexpression increases DEPDC1 protein levels and promotes lung squamous cell carcinoma tumorigenesis, while METTL5 knockdown inhibits proliferation and migration. Cell and animal experiments, overexpression/knockdown, western blot for DEPDC1 protein, in vivo tumor models Frontiers in oncology Medium 40018408
2025 DEPDC1 physically interacts with KIF20A (confirmed by Co-IP in liposarcoma cells), and KIF20A deletion partially mitigates the pro-malignant effects of DEPDC1 and suppresses PI3K/AKT/mTOR signaling pathway activation driven by DEPDC1. Co-immunoprecipitation, siRNA knockdown, overexpression, western blot for PI3K/AKT/mTOR pathway, functional cellular assays Frontiers in endocrinology Medium 40600015

Source papers

Stage 0 corpus · 41 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2007 Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 93 17452976
2010 Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer research 86 20587513
2016 Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. Cancer letters 58 27984115
2018 DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC. Cancer letters 51 30419349
2015 DEPDC1 is a novel cell cycle related gene that regulates mitotic progression. BMB reports 45 25902835
2017 DEPDC1 promotes cell proliferation and tumor growth via activation of E2F signaling in prostate cancer. Biochemical and biophysical research communications 44 28634077
2014 DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis. Nature cell biology 41 25064737
2017 DEPDC1 is required for cell cycle progression and motility in nasopharyngeal carcinoma. Oncotarget 37 28969015
2019 DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway. Oncology reports 31 31322256
2021 Artemisia argyi Essential Oil Inhibits Hepatocellular Carcinoma Metastasis via Suppression of DEPDC1 Dependent Wnt/β-Catenin Signaling Pathway. Frontiers in cell and developmental biology 27 34268303
2023 Glycolysis-Related Gene Analyses Indicate That DEPDC1 Promotes the Malignant Progression of Oral Squamous Cell Carcinoma via the WNT/β-Catenin Signaling Pathway. International journal of molecular sciences 26 36768316
2021 Linc-ROR facilitates progression and angiogenesis of hepatocellular carcinoma by modulating DEPDC1 expression. Cell death & disease 22 34741030
2019 DEPDC1 promotes cell proliferation and suppresses sensitivity to chemotherapy in human hepatocellular carcinoma. Bioscience reports 20 31189746
2024 DEPDC1 as a metabolic target regulates glycolysis in renal cell carcinoma through AKT/mTOR/HIF1α pathway. Cell death & disease 19 39068164
2017 Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells. Journal of neuro-oncology 19 28555424
2020 DEPDC1 up-regulates RAS expression to inhibit autophagy in lung adenocarcinoma cells. Journal of cellular and molecular medicine 18 33021072
2022 SIRT1 enhances oxaliplatin resistance in colorectal cancer through microRNA-20b-3p/DEPDC1 axis. Cell biology international 15 36200529
2020 NNK-mediated upregulation of DEPDC1 stimulates the progression of oral squamous cell carcinoma by inhibiting CYP27B1 expression. American journal of cancer research 15 32642287
2017 Phosphorylation of DEPDC1 at Ser110 is required to maintain centrosome organization during mitosis. Experimental cell research 14 28602627
2022 Long non-coding RNA DEPDC1-AS1 promotes proliferation and migration of human gastric cancer cells HGC-27 via the human antigen R-F11R pathway. The Journal of international medical research 13 35466755
2021 ALPK2 acts as tumor promotor in development of bladder cancer through targeting DEPDC1A. Cell death & disease 13 34210956
2024 Exosomal miR-130b-3p suppresses metastasis of non-small cell lung cancer cells by targeting DEPDC1 via TGF-β signaling pathway. International journal of biological macromolecules 12 38960258
2022 DEPDC1 as a crucial factor in the progression of human osteosarcoma. Cancer medicine 12 36479633
2017 Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. Oncoimmunology 12 28919988
2023 DEPDC1 and KIF4A synergistically inhibit the malignant biological behavior of osteosarcoma cells through Hippo signaling pathway. Journal of orthopaedic surgery and research 11 36849972
2022 miR-455-5p enhances 5-fluorouracil sensitivity in colorectal cancer cells by targeting PIK3R1 and DEPDC1. Open medicine (Warsaw, Poland) 11 35582195
2022 Silencing eL31 suppresses the progression of colorectal cancer via targeting DEPDC1. Journal of translational medicine 11 36309731
2022 FOXO3a‑modulated DEPDC1 promotes malignant progression of nephroblastoma via the Wnt/β‑catenin signaling pathway. Molecular medicine reports 9 35795985
2024 FOXM1/DEPDC1 feedback loop promotes hepatocarcinogenesis and represents promising targets for cancer therapy. Cancer science 7 39004911
2022 FOXM1 is regulated by DEPDC1 to facilitate development and metastasis of oral squamous cell carcinoma. Frontiers in oncology 7 36072787
2023 S100A16 cooperates with DEPDC1 to promote the progression and angiogenesis of nephroblastoma through PI3K/Akt/mTOR pathway. Polish journal of pathology : official journal of the Polish Society of Pathologists 6 37955537
2021 [DEPDC1 is Highly Expressed in Lung Adenocarcinoma and Promotes Tumor Cell Proliferation]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 5 34134185
2024 Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer. PloS one 3 38564630
2024 Roles of DEPDC1 in various types of cancer (Review). Oncology letters 3 39296974
2025 YY1-mediated DUXAP8 facilitates HCC progression via modulating DEPDC1 expression. Clinical and experimental medicine 2 39992478
2025 The human 18S rRNA m6A methyltransferase METTL5 promotes tumorigenesis via DEPDC1 in lung squamous cell carcinoma. Frontiers in oncology 2 40018408
2024 DEPDC1 affects autophagy-dependent glycolysis levels in human osteosarcoma cells by modulating RAS/ERK signaling through TTK. Anti-cancer drugs 2 39016842
2026 TCF7L2/DEPDC1 axis contributes to tumor progression by promoting cell proliferation, aerobic glycolysis, and immunosuppression in pancreatic cancer. Clinical and experimental medicine 0 41851532
2026 Methylation-regulated miR-374a-5p and miR-374b-5p suppress glycolysis and malignant progression of head and neck squamous cell carcinoma by targeting DEPDC1. Frontiers in oncology 0 42222424
2025 DEPDC1 facilitated malignant phenotypes and disease progression of liposarcoma by modulating KIF20A. Frontiers in endocrinology 0 40600015
2025 LncRNA DEPDC1-AS1 drives the progression of endometrial carcinoma by regulating miR-508-3p. Discover oncology 0 41003831

Missed literature

Know a paper Affinage missed for DEPDC1? Flag it for the maintainers and the community.

No submissions yet.